Home ETF List About

Portfolio Holdings Detail for ISIN IE00B3VWM098
Stock Name / FundiShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
IssuerBlackrock
Entity holding fund iShares VII Public Limited Company
Entity TypeUmbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300Q7FFITMZ2PFZ28
ETF TickerCUS1(GBX) LSE
ETF TickerCUSS(USD) LSE
ETF TickerSXRG(EUR) F
ETF TickerCSUSS.MI(EUR) CXE
ETF TickerCSUSSz(USD) CXE
ETF TickerCUSS.LS(USD) CXE
ETF TickerCSUSS(EUR) ETF Plus
ETF TickerCUS1.L(GBP) LSE
ETF TickerCUSS.L(GBP) LSE

Holdings detail for CRNX

Stock NameCrinetics Pharmaceuticals Inc
TickerCRNX(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS22663K1079
LEI549300Q1CNFXK5P31D28

Show aggregate CRNX holdings

News associated with CRNX

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives $68.86 Consensus Price Target from Brokerages
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report) has been given a consensus rating of “Moderate Buy” by the nine research firms that are covering the stock, Marketbeat.com reports. Two research analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average twelve-month price objective […] - 2025-08-19 02:16:54
Crinetics Pharmaceuticals (NASDAQ:CRNX) Price Target Cut to $86.00 by Analysts at JMP Securities
Crinetics Pharmaceuticals (NASDAQ:CRNX – Free Report) had its target price reduced by JMP Securities from $90.00 to $86.00 in a report published on Monday,Benzinga reports. JMP Securities currently has a market outperform rating on the stock. Several other research firms have also recently weighed in on CRNX. HC Wainwright reaffirmed a “buy” rating and set […] - 2025-08-12 04:47:05
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Sold by Victory Capital Management Inc.
Victory Capital Management Inc. lowered its position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 10.7% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 251,331 shares of the company’s stock after selling 30,120 shares during the quarter. Victory Capital Management Inc.’s holdings in […] - 2025-07-25 06:06:53
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Average Recommendation of “Moderate Buy” from Brokerages
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report) has been given an average recommendation of “Moderate Buy” by the ten brokerages that are currently covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 12-month target price […] - 2025-07-22 07:55:07
New York State Common Retirement Fund Sells 17,508 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
New York State Common Retirement Fund lessened its holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 11.3% during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 137,918 shares of the company’s stock after selling 17,508 shares during the quarter. New York State Common […] - 2025-07-22 07:13:05
Teacher Retirement System of Texas Decreases Holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
Teacher Retirement System of Texas decreased its position in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 6.5% in the 1st quarter, Holdings Channel reports. The fund owned 22,442 shares of the company’s stock after selling 1,561 shares during the quarter. Teacher Retirement System of Texas’ holdings in Crinetics Pharmaceuticals were worth $753,000 […] - 2025-07-15 04:24:35
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Consensus Rating of “Moderate Buy” from Brokerages
Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the ten analysts that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a hold rating and nine have given a buy rating to the company. The average 1 year […] - 2025-07-02 04:30:55
Insider Selling: Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Insider Sells $3,141,877.09 in Stock
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report) insider Stephen F. Betz sold 97,483 shares of the stock in a transaction dated Thursday, June 12th. The stock was sold at an average price of $32.23, for a total transaction of $3,141,877.09. Following the transaction, the insider now owns 99,713 shares of the company’s stock, valued […] - 2025-06-19 05:10:52
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Acquired by Mackenzie Financial Corp
Mackenzie Financial Corp grew its holdings in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 8.8% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 5,422 shares of the company’s stock after purchasing an additional 440 shares during the period. Mackenzie Financial Corp’s holdings […] - 2025-06-05 06:18:55
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Average Rating of “Moderate Buy” from Brokerages
Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report) have received an average rating of “Moderate Buy” from the eleven ratings firms that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold rating and ten have given a buy rating to the company. The average 1 […] - 2025-06-02 02:10:52
State of Wyoming Makes New Investment in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
State of Wyoming purchased a new stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 985 shares of the company’s stock, valued at approximately $50,000. Several other large investors […] - 2025-05-30 05:06:48
Bank of America Corp DE Cuts Stock Holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
Bank of America Corp DE decreased its position in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 15.4% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 235,281 shares of the company’s stock after selling 42,792 shares during the period. Bank of America Corp DE’s holdings in Crinetics Pharmaceuticals were worth $12,030,000 […] - 2025-05-23 06:26:56
BNP Paribas Financial Markets Sells 5,683 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
BNP Paribas Financial Markets decreased its stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 27.1% in the fourth quarter, Holdings Channel.com reports. The fund owned 15,259 shares of the company’s stock after selling 5,683 shares during the period. BNP Paribas Financial Markets’ holdings in Crinetics Pharmaceuticals were worth $780,000 at the […] - 2025-05-23 04:58:51
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Purchases 6,719 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 14.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 53,163 shares of the company’s stock after acquiring an additional 6,719 shares during […] - 2025-05-21 05:40:53
Ameriprise Financial Inc. Has $18.16 Million Position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
Ameriprise Financial Inc. lifted its stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 110.8% during the fourth quarter, Holdings Channel reports. The fund owned 355,174 shares of the company’s stock after buying an additional 186,681 shares during the quarter. Ameriprise Financial Inc.’s holdings in Crinetics Pharmaceuticals were worth $18,159,000 as of […] - 2025-05-16 05:03:19
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Given Consensus Recommendation of “Moderate Buy” by Analysts
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report) has earned an average recommendation of “Moderate Buy” from the thirteen brokerages that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and twelve have assigned a buy recommendation to the company. The average 1 year target […] - 2025-05-08 02:22:53
Envestnet Asset Management Inc. Buys 8,751 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
Envestnet Asset Management Inc. boosted its position in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 16.1% during the 4th quarter, HoldingsChannel reports. The fund owned 63,077 shares of the company’s stock after buying an additional 8,751 shares during the quarter. Envestnet Asset Management Inc.’s holdings in Crinetics Pharmaceuticals were worth $3,225,000 as […] - 2025-04-25 04:24:46
Legal & General Group Plc Buys 12,538 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
Legal & General Group Plc lifted its position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 16.4% in the 4th quarter, HoldingsChannel.com reports. The fund owned 88,939 shares of the company’s stock after acquiring an additional 12,538 shares during the quarter. Legal & General Group Plc’s holdings in Crinetics Pharmaceuticals were worth $4,547,000 as […] - 2025-04-22 04:47:14
Crinetics Pharmaceuticals (NASDAQ:CRNX) Shares Unloaded Rep. Josh Gottheimer
Representative Josh Gottheimer (D-New Jersey) recently sold shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX). In a filing disclosed on April 10th, the Representative disclosed that they had sold between $1,001 and $15,000 in Crinetics Pharmaceuticals stock on March 19th. The trade occurred in the Representative’s “MORGAN STANLEY – SELECT UMA ACCOUNT # 1” account. Representative Josh […] - 2025-04-14 03:02:59
Corebridge Financial Inc. Buys 1,992 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
Corebridge Financial Inc. boosted its stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 4.8% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 43,599 shares of the company’s stock after buying an additional 1,992 shares during the period. Corebridge Financial Inc.’s holdings […] - 2025-04-02 06:46:52
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Bought by Vanguard Group Inc.
Vanguard Group Inc. grew its holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 44.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 9,089,391 shares of the company’s stock after acquiring an additional 2,801,736 shares during the quarter. Vanguard Group […] - 2025-04-02 05:24:53
16,000 Shares in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Purchased by KLP Kapitalforvaltning AS
KLP Kapitalforvaltning AS bought a new position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 16,000 shares of the company’s stock, valued at approximately $818,000. A number of other hedge funds have also added to […] - 2025-04-01 05:14:54
Crinetics Pharmaceuticals (NASDAQ:CRNX) Coverage Initiated at Stifel Nicolaus
Analysts at Stifel Nicolaus began coverage on shares of Crinetics Pharmaceuticals (NASDAQ:CRNX – Get Free Report) in a report released on Tuesday, MarketBeat Ratings reports. The firm set a “buy” rating and a $60.00 price target on the stock. Stifel Nicolaus’ price target would suggest a potential upside of 73.86% from the stock’s previous close. […] - 2025-03-27 04:00:59
Arizona State Retirement System Grows Holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
Arizona State Retirement System boosted its holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 21.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 23,469 shares of the company’s stock after purchasing an additional 4,168 shares during the […] - 2025-03-14 06:10:48
Assetmark Inc. Purchases 1,014 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
Assetmark Inc. raised its position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 5.9% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 18,161 shares of the company’s stock after acquiring an additional 1,014 shares during the quarter. Assetmark Inc.’s holdings in Crinetics Pharmaceuticals […] - 2025-03-12 06:11:03
Keybank National Association OH Has $478,000 Position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
Keybank National Association OH boosted its stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 14.4% in the 4th quarter, HoldingsChannel.com reports. The fund owned 9,352 shares of the company’s stock after purchasing an additional 1,176 shares during the quarter. Keybank National Association OH’s holdings in Crinetics Pharmaceuticals were worth $478,000 at […] - 2025-03-10 05:54:54
Handelsbanken Fonder AB Buys 2,800 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
Handelsbanken Fonder AB raised its stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 14.7% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 21,800 shares of the company’s stock after purchasing an additional 2,800 shares during the quarter. Handelsbanken Fonder AB’s holdings in Crinetics Pharmaceuticals were worth $1,115,000 at the end […] - 2025-02-28 07:25:04
New York State Common Retirement Fund Purchases 7,735 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
New York State Common Retirement Fund lifted its position in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 5.2% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 155,426 shares of the company’s stock after purchasing an additional 7,735 shares during the quarter. New York State Common Retirement Fund’s holdings in Crinetics […] - 2025-02-27 06:51:01
Add Up The Pieces: VBK Could Be Worth $335
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-02-13 13:24:24
TD Cowen Begins Coverage on Crinetics Pharmaceuticals (NASDAQ:CRNX)
Analysts at TD Cowen started coverage on shares of Crinetics Pharmaceuticals (NASDAQ:CRNX – Get Free Report) in a research note issued on Tuesday, MarketBeat.com reports. The firm set a “buy” rating on the stock. CRNX has been the subject of a number of other reports. Wolfe Research started coverage on shares of Crinetics Pharmaceuticals in […] - 2025-02-13 08:26:44

iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc CRNX holdings

DateNumber of CRNX Shares HeldBase Market Value of CRNX SharesLocal Market Value of CRNX SharesChange in CRNX Shares HeldChange in CRNX Base ValueCurrent Price per CRNX Share HeldPrevious Price per CRNX Share Held
2025-11-12 (Wednesday)68,459CRNX holding decreased by -225USD 2,931,414CRNX holding decreased by -17877USD 2,931,414-225USD -17,877 USD 42.82 USD 42.94
2025-11-11 (Tuesday)68,684USD 2,949,291CRNX holding increased by 102339USD 2,949,2910USD 102,339 USD 42.94 USD 41.45
2025-11-10 (Monday)68,684USD 2,846,952CRNX holding increased by 99592USD 2,846,9520USD 99,592 USD 41.45 USD 40
2025-11-07 (Friday)68,684USD 2,747,360CRNX holding decreased by -239707USD 2,747,3600USD -239,707 USD 40 USD 43.49
2025-11-06 (Thursday)68,684CRNX holding decreased by -225USD 2,987,067CRNX holding increased by 56367USD 2,987,067-225USD 56,367 USD 43.49 USD 42.53
2025-11-05 (Wednesday)68,909CRNX holding decreased by -2250USD 2,930,700CRNX holding decreased by -94269USD 2,930,700-2,250USD -94,269 USD 42.53 USD 42.51
2025-11-04 (Tuesday)71,159CRNX holding decreased by -450USD 3,024,969CRNX holding decreased by -43477USD 3,024,969-450USD -43,477 USD 42.51 USD 42.85
2025-11-03 (Monday)71,609CRNX holding decreased by -450USD 3,068,446CRNX holding decreased by -66121USD 3,068,446-450USD -66,121 USD 42.85 USD 43.5
2025-10-31 (Friday)72,059USD 3,134,567CRNX holding increased by 15853USD 3,134,5670USD 15,853 USD 43.5 USD 43.28
2025-10-30 (Thursday)72,059USD 3,118,714CRNX holding increased by 27383USD 3,118,7140USD 27,383 USD 43.28 USD 42.9
2025-10-29 (Wednesday)72,059USD 3,091,331CRNX holding increased by 60529USD 3,091,3310USD 60,529 USD 42.9 USD 42.06
2025-10-28 (Tuesday)72,059CRNX holding increased by 675USD 3,030,802CRNX holding decreased by -134365USD 3,030,802675USD -134,365 USD 42.06 USD 44.34
2025-10-27 (Monday)71,384USD 3,165,167CRNX holding increased by 239137USD 3,165,1670USD 239,137 USD 44.34 USD 40.99
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of CRNX by Blackrock for IE00B3VWM098

Show aggregate share trades of CRNX

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-11-12SELL-22543.48042.050 42.193USD -9,493 38.22 Loss of -893 on sale
2025-11-06SELL-22543.89042.380 42.531USD -9,569 38.15 Loss of -986 on sale
2025-11-05SELL-2,25043.20041.410 41.589USD -93,575 38.12 Loss of -7,796 on sale
2025-11-04SELL-45042.78041.510 41.637USD -18,737 38.10 Loss of -1,591 on sale
2025-11-03SELL-45043.33542.075 42.201USD -18,990 38.08 Loss of -1,856 on sale
2025-10-28BUY67542.06044.100 43.896USD 29,630 37.97
2025-10-24SELL-22540.99041.520 41.467USD -9,330 37.92 Loss of -798 on sale
2025-10-15BUY1,35044.15045.960 45.779USD 61,802 37.76
2025-10-02BUY22541.51042.177 42.110USD 9,475 37.72
2025-09-30BUY45041.65043.480 43.297USD 19,484 37.68
2025-08-21SELL-22529.40029.885 29.837USD -6,713 37.67 Profit of 1,763 on sale
2025-07-31BUY67528.59029.550 29.454USD 19,881 37.78
2025-07-28SELL-22530.30031.360 31.254USD -7,032 37.93 Profit of 1,502 on sale
2025-06-30SELL-45028.76030.351 30.192USD -13,586 38.79 Profit of 3,868 on sale
2025-06-25SELL-22530.41030.995 30.937USD -6,961 38.97 Profit of 1,807 on sale
2025-06-20SELL-45030.16030.860 30.790USD -13,856 39.15 Profit of 3,764 on sale
2025-05-23BUY22529.76030.545 30.467USD 6,855 40.46
2025-05-19SELL-22530.95031.920 31.823USD -7,160 40.80 Profit of 2,020 on sale
2025-05-15SELL-67531.21031.380 31.363USD -21,170 40.97 Profit of 6,485 on sale
2025-05-12SELL-22533.32033.575 33.550USD -7,549 41.22 Profit of 1,725 on sale
2025-05-09SELL-22530.68034.340 33.974USD -7,644 41.31 Profit of 1,651 on sale
2025-04-30SELL-22533.39033.800 33.759USD -7,596 41.90 Profit of 1,831 on sale
2025-04-24SELL-45033.39033.460 33.453USD -15,054 42.26 Profit of 3,961 on sale
2025-04-22BUY2,70731.27031.300 31.297USD 84,721 42.47
2025-04-17SELL-21630.42030.580 30.564USD -6,602 42.86 Profit of 2,655 on sale
2025-04-15SELL-64829.66030.460 30.380USD -19,686 43.15 Profit of 8,272 on sale
2025-04-14SELL-64829.78030.340 30.284USD -19,624 43.29 Profit of 8,429 on sale
2025-04-09SELL-86427.66027.850 27.831USD -24,046 43.82 Profit of 13,813 on sale
2025-04-07SELL-1,51226.38027.230 27.145USD -41,043 44.23 Profit of 25,837 on sale
2025-04-04SELL-2,17026.89028.535 28.370USD -61,564 44.44 Profit of 34,864 on sale
2025-03-31BUY21633.54034.545 34.444USD 7,440 44.90
2025-03-19SELL-43434.67035.000 34.967USD -15,176 45.99 Profit of 4,783 on sale
2025-03-14SELL-1,30234.47035.630 35.514USD -46,239 46.47 Profit of 14,261 on sale
2025-03-13SELL-43435.04036.000 35.904USD -15,582 46.63 Profit of 4,655 on sale
2025-03-12SELL-7,37835.40035.540 35.526USD -262,111 46.79 Profit of 83,130 on sale
2025-03-07SELL-43433.28034.145 34.059USD -14,781 47.39 Profit of 5,784 on sale
2025-03-06SELL-65134.11034.455 34.421USD -22,408 47.59 Profit of 8,573 on sale
2025-03-03SELL-21734.14036.500 36.264USD -7,869 48.24 Profit of 2,600 on sale
2025-02-28BUY10,96435.78035.930 35.915USD 393,772 48.45
2025-02-26SELL-18532.55033.503 33.408USD -6,180 48.98 Profit of 2,880 on sale
2025-02-25SELL-55532.30034.795 34.545USD -19,173 49.26 Profit of 8,169 on sale
2025-02-18BUY92535.53036.477 36.382USD 33,654 50.50
2025-02-13BUY18535.26035.850 35.791USD 6,621 51.41
2025-02-12BUY18535.21035.220 35.219USD 6,516 51.74
2025-02-11BUY55534.93036.660 36.487USD 20,250 52.09
2025-02-06BUY1,66538.71039.720 39.619USD 65,966 53.07
2025-01-27BUY18538.21040.255 40.051USD 7,409 56.04
2024-12-30BUY92050.67051.280 51.219USD 47,121 57.37
2024-12-06BUY73658.87059.577 59.506USD 43,797 57.35
2024-12-05BUY18457.69058.270 58.212USD 10,711 57.34
2024-12-04BUY92057.11058.940 58.757USD 54,056 57.35
2024-11-29BUY92057.20057.810 57.749USD 53,129 57.38
2024-11-27BUY73657.67058.060 58.021USD 42,703 57.36
2024-11-26BUY18456.77056.980 56.959USD 10,480 57.38
2024-11-25BUY5,54356.09057.420 57.287USD 317,542 57.44
2024-11-21BUY83557.03058.035 57.934USD 48,375 57.54
2024-11-20BUY50156.07056.430 56.394USD 28,253 57.62
2024-11-18BUY2,00453.70055.050 54.915USD 110,050 58.02
2024-11-12BUY1,32858.78060.480 60.310USD 80,092 57.97
2024-11-08BUY83060.69060.930 60.906USD 50,552 57.77
2024-11-07BUY2,49059.81060.170 60.134USD 149,734 57.62
2024-11-06BUY33259.16060.905 60.730USD 20,163 57.49
2024-10-31BUY16655.96056.540 56.482USD 9,376 57.82
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of CRNX

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-19291,81110422,19069.1%
2025-09-18255,3114,887441,31757.9%
2025-09-17188,9560259,13872.9%
2025-09-16203,55446341,72459.6%
2025-09-15274,63530448,71661.2%
2025-09-12212,9184332,54464.0%
2025-09-11387,8134,439687,67356.4%
2025-09-10271,583180472,48457.5%
2025-09-09435,55110,514645,58767.5%
2025-09-08321,931100446,00772.2%
2025-09-05341,7345,833547,12962.5%
2025-09-04381,1280505,16375.4%
2025-09-03545,8963,603690,21679.1%
2025-09-02320,4581,530581,10855.1%
2025-08-29302,5020582,65751.9%
2025-08-28200,7180302,61166.3%
2025-08-27102,469343177,21257.8%
2025-08-26112,4740194,56757.8%
2025-08-25165,2040263,11362.8%
2025-08-22187,7583,090538,67734.9%
2025-08-21185,8541,565714,28426.0%
2025-08-2088,34712180,94748.8%
2025-08-19127,0621,989256,81349.5%
2025-08-1898,4620154,91563.6%
2025-08-15272,2452,909364,11374.8%
2025-08-14195,4155,120386,30750.6%
2025-08-13180,925108441,79841.0%
2025-08-12123,2510304,48140.5%
2025-08-11254,7141,686471,53454.0%
2025-08-08427,52471845,09450.6%
2025-08-07232,9900429,93154.2%
2025-08-06245,049453455,36053.8%
2025-08-05201,4371,908582,44934.6%
2025-08-04105,80412271,83338.9%
2025-08-01189,908631307,78961.7%
2025-07-31156,5220272,30957.5%
2025-07-30177,6080284,86262.3%
2025-07-29186,6501,295330,97456.4%
2025-07-28135,934800165,42782.2%
2025-07-25170,240173313,56454.3%
2025-07-24100,55482184,82354.4%
2025-07-23119,806200158,50575.6%
2025-07-22102,666226190,44753.9%
2025-07-21154,0050288,63153.4%
2025-07-18184,8791,777371,36049.8%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.